CORRIGENDUM

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]

Price DB, Henley W, Cançado JED, et al. *Int J Chron Obstruct Pulmon Dis*. 2022;17:355–370

On page 356, last paragraph of the Introduction section, the paragraph should be corrected from “...Collectively, there is a requirement for a real- world study comparing the use of extrafine particle fixed dose combination beclometasone dipropionate (ef-FDC-BDP; with a MMAD of 1.1µm in FOSTER[®] and TRIMBOW[®] NEXTHALER[®] DPIs and 1.3µm in FOSTER[®] pMDI) with other ICSs, such as fine particle fluticasone (fp-FDC-F; with a MMAD of 3.9µm and 3.2µm for propionate (SERETIDE[®] DISKUS[®]) and furoate (RELVAR[®] ELLIPTA[®]) esters respectively).^{21–23} to “...Collectively, there is a requirement for a real-world study comparing the use of extrafine particle fixed dose combination beclometasone dipropionate (ef-FDC-BDP; with a MMAD of 1.1µm in TRIMBOW[®] pMDI and 1.3µm in FOSTER[®] pMDI) with other ICSs, such as fine particle fluticasone (fp-FDC-F; with a MMAD of 3.9µm and 3.2µm for propionate (SERETIDE[®] DISKUS[®]) and furoate (RELVAR[®] ELLIPTA[®]) esters respectively).^{21–23}

The authors apologize for this error and advise they do not affect the results of the paper.

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

<https://doi.org/10.2147/COPD.S363875>

Received: 24 February 2022
Accepted: 24 February 2022
Published: 7 March 2022

International Journal of Chronic Obstructive Pulmonary Disease 2022;17 489

489

© 2022 Price et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).